United States Compounding Pharmacies Market Report and Forecast 2024-2032

United States Compounding Pharmacies Market Report and Forecast 2024-2032

Market Outlook

According to the report the United States compounding pharmacies market is projected to grow at a CAGR of 6.6% between 2024 and 2032 to reach a value of about USD 28.19 billion by 2032. Aided by the growing demand for personalised medications and the increasing prevalence of chronic diseases, the market is expected to grow significantly by 2032.

Compounding pharmacies play a crucial role in the healthcare system by creating customised medications tailored to the specific needs of patients. These pharmacies modify existing medications, create formulations that are not commercially available, and provide solutions for patients with allergies, paediatric requirements, or those needing unique dosage forms.

The United States compounding pharmacies market growth is primarily driven by the rising geriatric population and the increasing incidence of chronic diseases. As these conditions often require specialised medication regimens, compounding pharmacies are increasingly sought after for their ability to create bespoke solutions. Furthermore, the limitations of mass-produced pharmaceuticals in meeting individual patient needs are leading to a heightened demand for compounded medications.

The market is also benefiting from technological advancements in pharmaceutical compounding. According to the United States compounding pharmacies market analysis, state-of-the-art equipment and innovative techniques are enabling compounding pharmacies to produce more accurate and effective medications, enhancing patient outcomes. The adoption of digital technologies and automation in compounding processes is further streamlining operations and ensuring consistency in the quality of compounded medications.

Another factor boosting the United States compounding pharmacies market demand is the increasing awareness among healthcare professionals and patients about the advantages of compounded medications. Compounded drugs offer the flexibility to adjust dosages, eliminate non-essential ingredients, and create formulations that are not commercially available, providing significant benefits for patients with specific medical requirements.

The market landscape is characterised by the presence of several key players who are focusing on expanding their service offerings and enhancing their compounding capabilities. Strategic collaborations, investments in research and development, and the adoption of advanced compounding technologies are some of the key initiatives undertaken by market players to consolidate their position.

Therefore, considering all the factors, the United States compounding pharmacies market is poised for significant growth in the coming years. Driven by the rising demand for personalised medications, advancements in compounding technologies, and the increasing prevalence of chronic diseases, the market presents ample opportunities for growth and innovation.

Market Segmentation

The market can be divided based on type, compounding type, sterility, therapeutic area, distribution channel, and application.

Market Breakup by Type

• Oral
• Topical
• Suppositories
• Others

Market Breakup by Compounding Type

• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)
• Others

Market Breakup by Sterility

• Sterile
• Non-sterile

Market Breakup by Therapeutic Area

• Pain Management
• Hormone Replacement Therapy (HRT)
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online
• Others

Market Breakup by Application

• Paediatric
• Adult
• Geriatric
• Veterinary
• Others

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States compounding pharmacies market. Some of the major players explored in the report are as follows:

• Fagron N.V.
• PharMedium Services, LLC
• Fresenius Kabi Canada
• Others